<DOC>
	<DOCNO>NCT00077376</DOCNO>
	<brief_summary>This phase II trial study well give trastuzumab together ixabepilone carboplatin work treat patient HER2/neu-positive metastatic breast cancer . Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , ixabepilone carboplatin , work different way stop tumor cell divide stop grow die . Combining trastuzumab ixabepilone carboplatin may kill tumor cell .</brief_summary>
	<brief_title>Trastuzumab , Ixabepilone , Carboplatin Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine response rate ( determine RECIST criterion ) combination therapy Ixabepilone ( BMS-247550 ) , trastuzumab , carboplatin patient metastatic breast cancer know overexpress HER2 . SECONDARY OBJECTIVES : I . To determine time disease progression ( TTP ) time treatment failure ( TTF ) treatment Ixabepilone ( BMS-247550 ) , trastuzumab carboplatin patient metastatic breast cancer know overexpress HER2 . II . To determine toxicity combination therapy Ixabepilone ( BMS-247550 ) , trastuzumab carboplatin patient metastatic breast cancer know overexpress HER2 . III . To evaluate overall survival ( OS ) combination therapy Ixabepilone ( BMS-247550 ) , trastuzumab , carboplatin patient metastatic breast cancer know overexpress HER2 . IV . To correlate level phospho-STAT3 level HER2 , Survivin EGFR expression measure tissue immunohistochemistry . OUTLINE : This multicenter study . Induction therapy : Patients receive trastuzumab ( HerceptinÂ® ) IV 30 minutes* day 1 , 8 , 15 , 22 ixabepilone IV 1 hour carboplatin IV 1 hour day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence unacceptable toxicity . NOTE : *Trastuzumab give 90 minute day 1 course 1 ( induction therapy ) . Maintenance therapy : Patients receive trastuzumab IV 90 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month 3 year study entry . PROJECTED ACCRUAL : A total 10-60 patient accrue study within 1-6 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Patients histologically confirm adenocarcinoma breast metastatic know overexpress HER2/neu receive prior chemotherapy metastatic breast cancer ; prior hormonal therapy metastatic disease allow ; NOTE : protocol , HER2 overexpression define 3+ HER2 positivity measure immunohistochemistry use HercepTest ( DAKO ) HER2 gene amplification measure fluorescent insitu hybridization ( FISH , e.g . Vysis ) ; representative diagnostic tissue must submit central diagnostic review Patients must pregnant breast feed teratogenic potential drug ; recommend female childbearing potential blood test urine study within 2 week prior registration rule pregnancy ; woman childbearing potential sexually active male must strongly advise use accept effective nonhormonal method contraception Patients must least one objective measurable disease parameter ; baseline measurement evaluation use RECIST criterion guideline must obtain within 4 week prior registration study ; NOTE : area disease record followed Patients must ECOG performance status 0 1 Patients must disease free prior malignancy &gt; = 5 year exception curatively treat basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix Patients must history untreated brain metastasis brain metastasis currently undergoing radiation ; patient brain metastasis represent sole site disease eligible study ; patient previously treat brain metastasis respond brain radiotherapy and/or surgery continue response eligible provide brain site measurable disease Patients must peripheral neuropathy grade Patients must history prior severe ( grade 3 4 ) hypersensitivity reaction drug formulate polyoxyethylated castor oil ( Cremophor EL ) Patients must leave ventricular ejection fraction MUGA scan echocardiogram lower institutional limit normal obtain within 6 week prior registration Patients must history New York Heart Association class 3 4 heart failure Serum creatinine = &lt; 1.5 mg/dl Granulocytes &gt; = 1500/mm^3 Platelets &gt; = 100,000/mm^3 SGOT ( AST ) SGPT ( ALT ) = &lt; 1.5 x upper limit normal ( unless liver involved tumor , case SGOT ( AST ) SGPT ( ALT ) = &lt; 2.0 x upper limit normal ) Patients must history prior therapy trastuzumab ( Herceptin ) , Ixabepilone ( BMS247550 ) carboplatin metastatic disease ; patient develop metastatic disease = &lt; 6 month complete adjuvant trastuzumab ( Herceptin ) , paclitaxel , docetaxel , carboplatin , Ixabepilone ( BMS247550 ) consider prior therapy metastatic disease exclude study participation Patients must receive cumulative dose doxorubicin great 360 mg/m^2 epirubicin great 640 mg/m^2 Concurrent use hormonal therapy permit ; concurrent radiation therapy permit ; hormonal therapy must discontinue &gt; = 1 week prior registration ; radiation therapy must complete &gt; = 2 week prior registration Patients may prior radiation therapy , previously irradiate tumor use assess clinical response ; patient eligible area measurable disease ; exception give patient tumor recurrence area receive adjuvant radiation treatment , axilla chest wall</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>